ArticleDementia and geriatric cognitive disorders extra2011
Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease.
Article in Dementia and geriatric cognitive disorders extra, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Systemic Metabolism and Mitochondria in the Mechanism of Alzheimer's Disease: Finding Potential Therapeutic Targets.International journal of molecular sciences · 2023Review
- Copper, Iron, Selenium and Lipo-Glycemic Dysmetabolism in Alzheimer's Disease.International journal of molecular sciences · 2021Review
- Alteration of Iron Concentration in Alzheimer's Disease as a Possible Diagnostic Biomarker Unveiling Ferroptosis.International journal of molecular sciences · 2021Review
- Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer's disease pathology.Alzheimer's research & therapy · 2020Article
- Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology.Neurobiology of disease · 2020Observational
- Association of Plasma Transferrin With Cognitive Decline in Patients With Mild Cognitive Impairment and Alzheimer's Disease.Frontiers in aging neuroscience · 2020Article
- Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2016Review
- Redox Imbalance and Viral Infections in Neurodegenerative Diseases.Oxidative medicine and cellular longevity · 2016Review
- Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy.Journal of neural transmission (Vienna, Austria : 1996) · 2014Article
- Relationship between ceruloplasmin and oxidative biomarkers including ferritin among healthy Japanese.Journal of clinical biochemistry and nutrition · 2013Article
- Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies.Neuropsychiatric disease and treatment · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDS/
aimsThe oxidative activity of ceruloplasmin (CP) in serum has been found to be lowered in patients with Alzheimer's disease (AD). We investigated whether changes in CP were reflected by altered iron parameters in AD patients.
methodsIron parameters, and CP concentration, activity and specific activity were determined in the serum of 41 AD patients and controls.
resultsCP activity and specific activity were significantly lower in the AD patients. CP concentration and activity were negatively correlated with the ferritin concentration in both groups. CP concentration was positively correlated with age in the control group but not in the patients group.
conclusionThe lowered CP activity in the serum of AD patients was not reflected by the iron parameters. As CP concentration only rises with age in the controls, this may indicate failing adaption to age-related alterations in iron metabolism in AD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.